Eisai (Suzhou) Trading Co., Ltd.

Eisai's founder, Toyoji Naito, is born on August 15 in Ito, Fukui, Japan.

Toyoji leaves his village at age 15, heading west to find employment in Osaka.

Toyoji is employed at Winkel Shokai in Kobe, taking night courses in foreign languages and bookkeeping.

Toyoji leaves Winkel Shokai after being drafted into the Japanese Imperial Guard.

After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe.

World War I begins.

Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd.

Toyoji embarks on a seven-month business tour of India and Southeast Asia.

World War I ends.

Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil Castalol and analgesic cream Salomethyl.

The Great Kanto Earthquake strikes, causing Tanabe Motosaburo Store Co., Ltd. to fall on hard times, including the main store in Tokyo burning down.

Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, Animasa. Toyoji coins the term for 'high blood pressure' in its ad campaign.

A Salomethyl newspaper ad created by Toyoji wins the Best Advertisement Award in Japan's Society for the Promotion of Newspaper Advertising.

Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo.

Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States.

Nihon Eisai is established, focusing on in-house R&D to create new medicines.

Sakuragaoka Laboratory Co., Ltd. launches vitamin E product Juvela and Japan's first sanitary tampon Sampon.

World War II begins.

Nihon Eisai Co., Ltd., the predecessor of Eisai, is established in Saitama.

Sakuragaoka Laboratory Co., Ltd. and Nihon Eisai Co., Ltd. merge under the name Nihon Eisai Co., Ltd.

World War II ends.

Nihon Eisai Co., Ltd.'s contraceptive suppository Sampoon receives official approval from the Japanese government.

Nihon Eisai Co., Ltd. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets and motion sickness remedy Travelmin.

The company changes its name from Nihon Eisai Co., Ltd. to Eisai Co., Ltd.

Eisai rolls out its first three-year mid-term plan. Its Head Office building in Tokyo is completed.

Eisai opens its Taipei Office in Taiwan and is listed on the Tokyo and Osaka Stock Exchanges.

Toyoji Naito receives the Japan Marketing Award. The Tokyo Olympics take place.

The Kawashima Plant in Gifu is completed. Toyoji Naito is appointed chairman, Yuji Naito as president, and a three-tier director system is introduced.

Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.

PT Eisai Indonesia is established as a manufacturing and sales subsidiary in Indonesia.

Toyoji Naito opens the Naito Museum of Pharmaceutical Science and Industry in Gifu.

The first oil crisis occurs due to conflict in the Middle East.

Eisai (Malaysia) Sdn. Bhd. and Hi-Eisai Pharmaceutical Inc. are established. Neuquinon is launched in Japan.

Juvelux, a vitamin E product, is launched in Japan.

Founder Toyoji Naito passes away at age 89.

Eisai Asia Regional Services Pte. Ltd. is established in Singapore.

Eisai U.S.A. Inc. is established in California, and the Misato Plant begins pharmaceutical manufacturing in Saitama.

The Tsukuba Research Laboratories open in Ibaraki.

Eisai Chemical Co., Ltd. (now Kashima Plant) is established in Ibaraki for API manufacturing.

Gastritis and gastric ulcer treatment Selbex is launched in Japan.

Eisai supports healthcare awards and establishes the Boston Research Institute in Massachusetts.

President Yuji Naito steps down, Haruo Naito becomes president; Eisai America and Europe subsidiaries are established.

Eisai Machinery GmbH in Germany and Eisai (Thailand) Marketing Co., Ltd. are established.

Eisai London Research Laboratories is established; Japan's bubble economy bursts.

Eisai Hong Kong Co., Ltd. and Beijing Representative Office are established; Shenyang joint venture is formed; Eisai celebrates 50th anniversary.

Eisai adopts current mission and objectives; Eisai Corporation of North America is established.

Eisai Inc. in the US, Eisai Ltd. in the UK, and Eisai Deutschland GmbH in Germany are established.

Eisai S.A. in France and Eisai Suzhou Pharmaceutical Co., Ltd. in China are established.

KAN Research Institute in Osaka, Eisai Korea Inc., and North Carolina Plant are established; Aricept and Pariet launched internationally.

Aricept launched in France; Pariet launched in Germany and UK.

Pariet launched as AcipHex in the US; Aricept launched in Japan.

The 9/11 terrorist attacks occur; Eisai Farmacéutica S.A. established in Madrid.

Eisai Medical Research Inc. established; adopts 'Company with Committees' system.

Eisai Europe Ltd. established in London; Eisai Pharmaceuticals India Pvt. Ltd. in Mumbai.

Eisai S.r.l. in Italy, Pharma AG in Switzerland, and other subsidiaries established; Yuji Naito passes away.

Eisai launches 'Dramatic Leap Plan'; new subsidiaries in Australia, Singapore, Portugal, and others established.

Eisai Manufacturing Ltd. established in UK; acquires Morphotek Inc. in US; new subsidiaries in India and Belgium.

Eisai acquires MGI Pharma; launches Humira in Japan.

Eisai establishes subsidiaries in Austria and UK; opens European Knowledge Centre; launches Equfina in Japan.

Eisai establishes subsidiaries in Canada and China; launches Halaven in US; signs WHO agreement.

Great East Japan Earthquake; launches sixth mid-term plan 'HAYABUSA'; establishes subsidiaries in Brazil and Mexico.

Signs London Declaration; launches Fycompa in Europe; Naito appointed FPMAJ president.

Establishes LLC in Moscow; co-establishes GHIT Fund; provides free lymphatic filariasis medicine to WHO.

Fycompa launched in US; Eisai China Holdings Ltd. established.

Lenvima launched in US, Japan, Europe; acquires Liaoning Tianyi Pharmaceutical.

Eisai launches 'EWAY2025'; establishes EA Pharma; launches Fycompa in Japan.

Joins partnership for NCDs; supports lymphatic filariasis elimination; collaborates with Biogen on Alzheimer's treatments.

Strategic collaboration for Lenvima with Merck; new Suzhou plant operational; Lenvima launched in China.

Eisai G2D2 in Massachusetts begins operation; launches Equfina in Japan; launches Fycompa and Halaven in China.

WHO declares COVID-19 a pandemic; launches brain health tool NouKNOW; DAYVIGO in US and Japan; establishes Vietnam subsidiary and Shanghai health company.

Launch of eighth mid-term plan 'EWAY Future & Beyond'; ADUHELM approved and launched in US; enters collaboration with Bristol-Myers Squibb; celebrates 80th anniversary.

Amends ADUHELM collaboration; makes Arteryex subsidiary; establishes subsidiaries in South Africa; signs Kigali Declaration; launches DHBL R&D organization.

LEQEMBI granted accelerated and traditional FDA approval; funds third phase of GHIT; establishes Theoria Technologies in Tokyo; launches LEQEMBI in Japan.